Xenetic Biosciences, Inc. (XBIO) News
Follow Xenetic Biosciences, Inc. (XBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Xenetic Biosciences, PeriNess Report First Patient Dosed in Study
The investigator-initiated study at Tel Aviv Sourasky University Medical Center is evaluating systemic DNase with CAR T cells for large B-cell lymphoma.
EQUITY | Oct 15, 2026, 12:46 PM UTC
L
Xenetic Biosciences updates investor presentation on Santersus share exchange, outlines pro forma valuation and 2027—2029 milestones
Xenetic Biosciences released an updated investor presentation on its proposed share exchange with Santersus, outlining an illustrative ~85%/15% pro—forma ownership split, estimated $141M valuation for Santersus and key c
REGULATION | Sep 23, 2026, 09:24 PM UTC
H
Crude Oil Down Over 3%; US Business Inventories Surge In July
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.1% on Wednesday. The Dow traded down 0.07% to 52,058.51 while the NASDAQ climbed 0.72% to 26,168.28. The S&P 500 also rose, gaini
LIVE | Sep 16, 2026, 04:33 PM UTC
H
Nasdaq Gains Over 100 Points; US Retail Sales Beat Estimates
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.02% to 52,103.62 while the NASDAQ climbed 0.
LIVE | Sep 16, 2026, 01:42 PM UTC
M
Xenetic Biosciences to merge with Santersus in all-stock deal
Xenetic Biosciences agreed to combine with privately held therapeutic medical-device company Santersus in an all-stock reverse merger. Xenetic said Santersus investors would own about 85% of the combined company, while c
EQUITY | Sep 16, 2026, 11:30 AM UTC
M
Xenetic Biosciences to acquire Santersus in all-stock exchange
Xenetic Biosciences entered a definitive all-stock share exchange to acquire Santersus, with pro forma ownership of ~15% for Xenetic holders and ~85% for Santersus holders, subject to approvals.
EQUITY | Sep 16, 2026, 11:03 AM UTC